Kane Biotech Management
Management criteria checks 3/4
Kane Biotech's CEO is Rob Huizinga, appointed in Apr 2025, has a tenure of less than a year. total yearly compensation is CA$239.43K, comprised of 44.1% salary and 55.9% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth $85.82K. The average tenure of the management team and the board of directors is 2.9 years and 4.1 years respectively.
Key information
Rob Huizinga
Chief executive officer
CA$239.4k
Total compensation
| CEO salary percentage | 44.13% |
| CEO tenure | less than a year |
| CEO ownership | 1.6% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -CA$2m |
| Jun 30 2025 | n/a | n/a | -CA$2m |
| Mar 31 2025 | n/a | n/a | -CA$3m |
| Dec 31 2024 | CA$239k | CA$106k | -CA$3m |
Compensation vs Market: Rob's total compensation ($USD175.21K) is below average for companies of similar size in the US market ($USD572.77K).
Compensation vs Earnings: Insufficient data to compare Rob's compensation with company performance.
CEO
Rob Huizinga (60 yo)
Dr. Robert B. Huizinga, also known as Rob, Ph.D. RN NNC, M.Sc. (Epi), CNeph(C), served as an Executive Vice President of Research at Aurinia Pharmaceuticals Inc. since June 2020 until October 31, 2022. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO | less than a year | CA$239.43k | 1.61% $ 85.8k | |
| Chief Financial Officer | 8.4yrs | CA$376.88k | 0.60% $ 31.8k | |
| Chief Quality Officer | 1.9yrs | CA$279.56k | no data | |
| Chief Scientific Officer & Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Investor Relations | no data | no data | no data | |
| Investor Relations Adviser | no data | no data | no data |
Experienced Management: KNBI.F's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO | 7.4yrs | CA$239.43k | 1.61% $ 85.8k | |
| Chief Scientific Officer & Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Chairman | 15.4yrs | CA$59.32k | 27.75% $ 1.5m | |
| Member of Scientific Advisory Board | 7.4yrs | CA$13.30k | no data | |
| Director | less than a year | no data | no data | |
| Chairman of Scientific Advisory Board | 7.4yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | 2.3yrs | CA$41.41k | no data |
Experienced Board: KNBI.F's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 21:23 |
| End of Day Share Price | 2026/01/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kane Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.